Here, we are going to share Suven Pharma Share Price Target 2025 to 2040 on the basis of its fundamental and technical analysis.
Suven Pharmaceuticals Limited is a Hyderabad-based pharmaceutical company that specializes in contract development and manufacturing (CDMO) services.
The company focuses on providing integrated solutions for the pharmaceutical industry, including process research and development, late-stage clinical development, and commercial manufacturing of new chemical entities and fine chemical intermediates.
Suven Pharma Share Key Information
| Company Name | Suven Pharmaceuticals Ltd |
| Headquarters | Hyderabad, India |
| Sectors | Pharmaceuticals & Drugs |
| Market Cap | ₹ 31,807.89 Cr. |
| No. of Shares | 25.46 Cr. |
| Book Value | ₹83.24 |
| Dividend Yield | 0% |
| ROCE | 21.27% |
| ROE | 16.03% |
| Face Value | ₹1 |
| Sales Growth | -22.94% |
| Profit Growth | -29.54% |
Suven Pharma Business Sector
Suven Pharma operates under a Contract Development and Manufacturing Organization (CDMO) model, which includes:
- Research and Development: Engaging in process research and development for new chemical entities.
- Manufacturing: Providing high-quality manufacturing services for pharmaceutical products.
- Regulatory Support: Offering regulatory assistance to ensure compliance with international standards.
- Partnerships: Collaborating with global pharmaceutical companies to develop and manufacture innovative drugs.
Board Members
- Mr. Venkat Jasti – Chairman and CEO
- Dr. S. R. S. Rao – Managing Director
- Mr. R. R. Kiran – Director
- Dr. R. S. S. Reddy – Independent Director
Suven Pharma Share Quarterly Results
| PARTICULARS | Mar 2024 | Jun 2024 |
|---|---|---|
| Net Sales | 243.52 | 222.09 |
| Total Expenditure | 171.38 | 139.05 |
| Operating Profit | 72.14 | 83.04 |
| Other Income | 16.87 | 17.95 |
| Interest | 2.29 | 1.60 |
| Depreciation | 15.67 | 12 |
| Exceptional Items | 0 | 0 |
| Profit Before Tax | 71.05 | 87.39 |
| Tax | 17.62 | 22.31 |
| Profit After Tax | 53.43 | 65.08 |
| Adjusted EPS (Rs) | 2.10 | 2.56 |
Suven Pharma Company Profits and Losses
| PARTICULARS | Mar 2023 | Mar 2024 |
|---|---|---|
| Net Sales | 1,330.08 | 1,024.99 |
| Total Expenditure | 739.39 | 615.09 |
| Operating Profit | 590.69 | 409.90 |
| Other Income | 44.55 | 55.09 |
| Interest | 12.75 | 7.43 |
| Depreciation | 43.10 | 48.79 |
| Exceptional Items | 0 | 0 |
| Profit Before Tax | 579.39 | 408.77 |
| Tax | 146.79 | 103.96 |
| Net Profit | 432.60 | 304.82 |
| Adjusted EPS (Rs.) | 16.99 | 11.97 |
Suven Pharma Share Price Target 2025-2040
| Year | Initial Target | Year-End Target |
|---|---|---|
| 2025 | ₹1325 | ₹1385 |
| 2026 | ₹1395 | ₹1492 |
| 2027 | ₹1499 | ₹1596 |
| 2028 | ₹1607 | ₹1752 |
| 2029 | ₹1765 | ₹1885 |
| 2030 | ₹1902 | ₹2061 |
| 2035 | ₹2765 | ₹3085 |
| 2040 | ₹3888 | ₹4250 |
Suven Pharma Share Price Target 2025
| Year/Month | Predicted Target |
|---|---|
| January 2025 | ₹1325 |
| February 2025 | ₹1339 |
| March 2025 | ₹1346 |
| April 2025 | ₹1352 |
| May 2025 | ₹1342 |
| June 2025 | ₹1329 |
| July 2025 | ₹1339 |
| August 2025 | ₹1353 |
| September 2025 | ₹1361 |
| October 2025 | ₹1366 |
| November 2025 | ₹1378 |
| December 2025 | ₹1385 |
Suven Pharma Share Price Target 2026
| Year/Month | Predicted Target |
|---|---|
| January 2026 | ₹1395 |
| February 2026 | ₹1399 |
| March 2026 | ₹1402 |
| April 2026 | ₹1415 |
| May 2026 | ₹1425 |
| June 2026 | ₹1439 |
| July 2026 | ₹1445 |
| August 2026 | ₹1459 |
| September 2026 | ₹1465 |
| October 2026 | ₹1472 |
| November 2026 | ₹1485 |
| December 2026 | ₹1492 |
Suven Pharma Share Price Target 2027
| Year/Month | Predicted Target |
|---|---|
| January 2027 | ₹1499 |
| February 2027 | ₹1507 |
| March 2027 | ₹1525 |
| April 2027 | ₹1539 |
| May 2027 | ₹1528 |
| June 2027 | ₹1541 |
| July 2027 | ₹1556 |
| August 2027 | ₹164 |
| September 2027 | ₹1552 |
| October 2027 | ₹1572 |
| November 2027 | ₹1585 |
| December 2027 | ₹1596 |
Suven Pharma Share Price Target 2028
| Year/Month | Predicted Target |
|---|---|
| January 2028 | ₹1607 |
| February 2028 | ₹1627 |
| March 2028 | ₹1639 |
| April 2028 | ₹1661 |
| May 2028 | ₹1652 |
| June 2028 | ₹1676 |
| July 2028 | ₹1687 |
| August 2028 | ₹1691 |
| September 2028 | ₹1702 |
| October 2028 | ₹1725 |
| November 2028 | ₹1739 |
| December 2028 | ₹1752 |
Suven Pharma Share Price Target 2029
| Year/Month | Predicted Target |
|---|---|
| January 2029 | ₹1765 |
| February 2029 | ₹1796 |
| March 2029 | ₹1777 |
| April 2029 | ₹1786 |
| May 2029 | ₹1802 |
| June 2029 | ₹1825 |
| July 2029 | ₹1837 |
| August 2029 | ₹1842 |
| September 2029 | ₹1856 |
| October 2029 | ₹1871 |
| November 2029 | ₹1859 |
| December 2029 | ₹1885 |
Suven Pharma Share Price Target 2030
| Year/Month | Predicted Target |
|---|---|
| January 2030 | ₹1902 |
| February 2030 | ₹1925 |
| March 2030 | ₹1937 |
| April 2030 | ₹1956 |
| May 2030 | ₹1945 |
| June 2030 | ₹1961 |
| July 2030 | ₹1975 |
| August 2030 | ₹1986 |
| September 2030 | ₹2012 |
| October 2030 | ₹2025 |
| November 2030 | ₹2037 |
| December 2030 | ₹2061 |
Suven Pharma Share Price Target 2035
| Year/Month | Predicted Target |
|---|---|
| January 2035 | ₹2765 |
| April 2035 | ₹2895 |
| July 2035 | ₹2962 |
| October 2035 | ₹3012 |
| December 2035 | ₹3085 |
Suven Pharma Share Price Target 2040
| Year/Month | Predicted Target |
|---|---|
| January 2040 | ₹3888 |
| April 2040 | ₹3952 |
| July 2040 | ₹4012 |
| October 2040 | ₹4125 |
| December 2040 | ₹4250 |
Suven Pharma Shareholding Pattern
| Terms | Percentage |
|---|---|
| Promoters | 50.1% |
| FIIs | 9.8% |
| DIIs | 17.43% |
| Others | 0% |
| Public | 22.67% |
Suven Pharma Company Competitors
- Piramal Pharma
- Laurus Lab
- Dr Redyy’s Lab
- Natco Pharma
- Lupin Ltd
Bull Case of Suven Pharma (Reasons to Invest)
Strong Market Demand: The increasing demand for pharmaceuticals globally can drive growth.
Innovative Pipeline: A robust pipeline of new chemical entities and partnerships with major pharma companies enhances potential revenue.
Quality Manufacturing: High-quality manufacturing capabilities can attract more clients in the CDMO space.
Regulatory Expertise: Strong regulatory compliance can facilitate smoother market entry for products.
Bear Case of Suven Pharma (Risks Involved)
Market Competition: Intense competition in the pharmaceutical sector may impact market share.
Regulatory Challenges: Potential regulatory hurdles can delay product launches and increase costs.
Dependency on Global Markets: Economic downturns in key markets may affect sales and profitability.
R&D Risks: High investment in R&D with uncertain outcomes can strain financial resources.
Suven Pharma Share Price Target: FAQ
What will be the target of Suven Pharma Share for the year 2025?
By the end of the year 2025, its share price can reach ₹1385.
What will be the target of Suven Pharma Share for the year 2026?
By the end of the year 2026, its share price can reach ₹1492.
What will be the target of Suven Pharma Share for the year 2027?
By the end of the year 2027, its share price can reach ₹1596.
What will be the target of Suven Pharma Share for the year 2028?
By the end of the year 2028, its share price can reach ₹1752.
What will be the target of Suven Pharma Share for the year 2029?
By the end of the year 2029, its share price can reach ₹1885.
What will be the target of Suven Pharma Share for the year 2030?
By the end of the year 2030 its share price can reach ₹2061.
What is the Current market cap of Suven Pharma company?
At present the market cap of this company is ₹ 31,807.89 Cr.
What is the NSE symbol of Suven Pharma company?
The symbol of this company in NSE exchange is SUVEBPHAR.
What is the BSE symbol of Suven Pharma company?
The symbol of this company in BSE exchange is 543064.
